AIRLINK 79.41 Increased By ▲ 1.02 (1.3%)
BOP 5.33 Decreased By ▼ -0.01 (-0.19%)
CNERGY 4.38 Increased By ▲ 0.05 (1.15%)
DFML 33.19 Increased By ▲ 2.32 (7.52%)
DGKC 76.87 Decreased By ▼ -1.64 (-2.09%)
FCCL 20.53 Decreased By ▼ -0.05 (-0.24%)
FFBL 31.40 Decreased By ▼ -0.90 (-2.79%)
FFL 9.85 Decreased By ▼ -0.37 (-3.62%)
GGL 10.25 Decreased By ▼ -0.04 (-0.39%)
HBL 117.93 Decreased By ▼ -0.57 (-0.48%)
HUBC 134.10 Decreased By ▼ -1.00 (-0.74%)
HUMNL 7.00 Increased By ▲ 0.13 (1.89%)
KEL 4.67 Increased By ▲ 0.50 (11.99%)
KOSM 4.74 Increased By ▲ 0.01 (0.21%)
MLCF 37.44 Decreased By ▼ -1.23 (-3.18%)
OGDC 136.70 Increased By ▲ 1.85 (1.37%)
PAEL 23.15 Decreased By ▼ -0.25 (-1.07%)
PIAA 26.55 Decreased By ▼ -0.09 (-0.34%)
PIBTL 7.00 Decreased By ▼ -0.02 (-0.28%)
PPL 113.75 Increased By ▲ 0.30 (0.26%)
PRL 27.52 Decreased By ▼ -0.21 (-0.76%)
PTC 14.75 Increased By ▲ 0.15 (1.03%)
SEARL 57.20 Increased By ▲ 0.70 (1.24%)
SNGP 67.50 Increased By ▲ 1.20 (1.81%)
SSGC 11.09 Increased By ▲ 0.15 (1.37%)
TELE 9.23 Increased By ▲ 0.08 (0.87%)
TPLP 11.56 Decreased By ▼ -0.11 (-0.94%)
TRG 72.10 Increased By ▲ 0.67 (0.94%)
UNITY 24.82 Increased By ▲ 0.31 (1.26%)
WTL 1.40 Increased By ▲ 0.07 (5.26%)
BR100 7,526 Increased By 32.9 (0.44%)
BR30 24,650 Increased By 91.4 (0.37%)
KSE100 71,971 Decreased By -80.5 (-0.11%)
KSE30 23,749 Decreased By -58.8 (-0.25%)

STOCKHOLM: Sweden's Public Health Agency on Wednesday recommended a temporary halt to the use of the Moderna Covid-19 vaccine among young adults, citing concerns over rare side effects to the heart.

It said the pause should initially be in force until December 1, explaining that it had received evidence of an increased risk of side effects such as inflammation of the heart muscle (myocarditis) and inflammation of the pericardium (pericarditis).

"The Public Health Agency has decided to pause the use of Moderna's vaccine Spikevax, for everyone born 1991 and after, for cautionary reasons," the agency said in a statement, adding that those groups should instead receive the Pfizer/BioNTech vaccine.

According to the agency, the risk seemed especially tied to the second dose of the Moderna vaccine and was more prevalent among young men and boys, and in the weeks just following the second jab.

The symptoms usually pass by themselves, but should be evaluated by a doctor, it added.

Moderna says its Covid-19 shot 93% effective six months after second dose

"Those who are vaccinated recently, with their first or second dose of Moderna's vaccine, don't need to feel worried because the risk is very minor, but it is good to know which symptoms you should be on the lookout for," state epidemiologist Anders Tegnell said in a statement.

Some 81,000 people in the age group have already received a first jab in Sweden, but they will not be offered a second, the agency said, adding that "discussions were ongoing about the best solution for this group."

The European Medicines Agency (EMA) authorised the emergency use of Moderna's Covid-19 vaccine for teens in July.

Comments

Comments are closed.